<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-4AE5TH68/2f1bc2d2-7688-499d-b129-a39916b5817b/PDF"><dcterms:extent>1032 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-4AE5TH68/ba316501-06f7-492e-90f4-ef549b863dad/TEXT"><dcterms:extent>40 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1992-2025"><edm:begin xml:lang="en">1992</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-4AE5TH68"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-FNIFVE9S" /><dcterms:issued>2022</dcterms:issued><dc:creator>Bošnjak, Maša</dc:creator><dc:creator>Cerovšek, Anja</dc:creator><dc:creator>Čemažar, Maja</dc:creator><dc:creator>Jesenko, Tanja</dc:creator><dc:creator>Markelc, Boštjan</dc:creator><dc:creator>Serša, Gregor</dc:creator><dc:format xml:lang="sl">številka:2</dc:format><dc:format xml:lang="sl">letnik:56</dc:format><dc:format xml:lang="sl">str. 164-172</dc:format><dc:identifier>DOI:10.2478/raon-2022-0009</dc:identifier><dc:identifier>COBISSID_HOST:105234179</dc:identifier><dc:identifier>ISSN:1318-2099</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-4AE5TH68</dc:identifier><dc:language>en</dc:language><dc:publisher xml:lang="sl">Association of Radiology and Oncology</dc:publisher><dcterms:isPartOf xml:lang="sl">Radiology and oncology (Ljubljana)</dcterms:isPartOf><dc:subject xml:lang="en">electrochemotherapy</dc:subject><dc:subject xml:lang="sl">elektrokemoterapija</dc:subject><dc:subject xml:lang="en">pancreas</dc:subject><dc:subject xml:lang="en">pancreatic cancer</dc:subject><dc:subject xml:lang="sl">rak trebušne slinavke</dc:subject><dc:subject xml:lang="sl">sunitinib</dc:subject><dc:subject xml:lang="sl">trebušna slinavka</dc:subject><dcterms:temporal rdf:resource="1992-2025" /><dc:title xml:lang="sl">Sunitinib potentiates the cytotoxic effect of electrochemotherapy in pancreatic carcinoma cells|</dc:title><dc:description xml:lang="sl">One of the new treatment options for unresectable locally advanced pancreatic cancer is electro-chemotherapy (ECT), a local ablative therapy that potentiates the entry of chemotherapeutic drugs into the cells, by the application of an electric field to the tumor. Its feasibility and safety were demonstrated in preclinical and clinical studies; however, there is a lack of preclinical studies assessing the actions of different drugs used in ECT, their mechanisms and interactions with other target drugs that are used in clinical practice. Materials and methods. The aim of the study was to determine the cytotoxicity of two chemotherapeutic drugs usually used in ECT (bleomycin and cisplatin) in the BxPC-3 human pancreatic carcinoma cell line and evaluate the interactions of ECT with the targeted drug sunitinib. First, the cytotoxicity of ECT using both chemotherapeutics was determined. In the next part, the interactions of ECT and sunitinib were evaluated through determination of combined cytotoxicity, sunitinib targets and kinetics of cell death.Results. The results demonstrate that ECT is effective in pancreatic cancer cell line, especially when bleomycin is used, with the onset of cell death in the first hours after the treatment, reaching a plateau at 20 hours after the treat-ment. Furthermore, we provide the rationale for combining ECT with bleomycin and the targeted drug sunitinib to potentiate cytotoxicity. The combined treatment of sunitinib and ECT was synergistic for bleomycin only at the high-est used concentration of bleomycin 0.14 µM, whereas with lower doses of bleomycin, this effect was not observed. The interaction of ECT and treatment with sunitinib was confirmed by course of the cell death, also indicating on synergism</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-4AE5TH68"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-4AE5TH68" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-4AE5TH68/2f1bc2d2-7688-499d-b129-a39916b5817b/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Društvo radiologije in onkologije</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-4AE5TH68/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-4AE5TH68" /></ore:Aggregation></rdf:RDF>